Novartis plans to close a British factory or lay off 400 employees!

Novartis chief executive vas Narasimhan recently reported that investors are moving towards the goal of integrating its manufacturing business into a more focused high-end technology The latest development is that the company plans to stop the Grimsby business in the UK, one of the three main manufacturing plants of Novartis, whose production team has a high reputation within the company The Grimsby plant in Novartis (source: Novartis) is known to cover 220 acres, some of which can be sold separately Novartis said that unless a buyer could be found, 400 workers would be out of work on appointments and would hit the local economy by at least £ 23m According to business live, local officials and Novartis met on February 12 to discuss how to implement the checkout process in the event of buyer failure After Novartis first announced the closure of the plant in 2018, a task force was set up to help workers and urban unemployed In September 2019, Novartis said that since the announcement of the closure plan, six companies have been engaged to discuss possible purchase issues But no progress has been announced since Novartis plans to cut jobs from April as it closes the plant and close the rest of its business by the end of 2020 Interestingly, Melanie onn, a former member of Grimsby, pressed Novartis to take on the responsibility of being a big employer before it was ready to leave But the MP lost his seat in the December 2019 election Melanie onn (source: grimsbytelegraph) raised funds for research and development as well as for the purchase of innovative drugs, and Novartis cut its operating costs In 2018, Novartis listed Grimsby as one of the five plants to be sold, closed or downsized The other four plants are located in Basel, schweizerhalle, Locarno and Stein, affecting 2000 jobs In October 2019, Novartis also launched a plan to close part of its production facilities at ringaskiddy plant in Ireland, consolidating its active pharmaceutical ingredients business in the region This will result in 320 employees losing their jobs Novartis has been shutting down and selling large and formula manufacturing facilities, and as the company moves to high margin specialty drugs (such as cell and gene therapy), it is abandoning longer-term drug and generic manufacturing Previously, Novartis added 450 jobs in one of Stein's cell and gene therapy departments to develop its gene and cell therapy production, mainly new drugs such as car-t drug kymriah and gene therapy zolgensma But these facilities are much smaller and require highly skilled workers, who need to reprogram cells and genes and then transplant them into patients for potential treatment Narasimhan has said that "a strong productivity plan will continue to be implemented with the goal of achieving absolute savings of $2 billion in technology operations, manufacturing, procurement and business services." At a conference call two weeks ago, he made it clear again that the company was improving its purchasing and manufacturing capabilities, reducing excess inventory, and more actively deploying data and digital products in the entire manufacturing network of Novartis Reference source: 400 Novartis workers prepare for job losses at U.K manufacturing site